miR‑107‑5p promotes tumor proliferation and invasion by targeting estrogen receptor‑α in endometrial carcinoma

Bao,Wei; Zhang,Yan; Li,Shuangdi; Fan,Qiong; Qiu,Meiting; Wang,Yanan; Li,Yanli; Ji,Xiaoning; Yang,Ye; Sang,Zhenyu; Xu,Wei; Yang,Yongbin; Wu,Sufang; Zhu,Yaping

doi:10.3892/or.2018.6936

miR‑107‑5p promotes tumor proliferation and invasion by targeting estrogen receptor‑α in endometrial carcinoma

Authors:
- Wei Bao
- Yan Zhang
- Shuangdi Li
- Qiong Fan
- Meiting Qiu
- Yanan Wang
- Yanli Li
- Xiaoning Ji
- Ye Yang
- Zhenyu Sang
- Wei Xu
- Yongbin Yang
- Sufang Wu
- Yaping Zhu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanghai General Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China, Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200030, P.R. China, Department of Obstetrics and Gynecology, Shanghai Ninth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China
Published online on: December 18, 2018 https://doi.org/10.3892/or.2018.6936
Pages: 1575-1585
Copyright: © Bao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aberrant expression of miR107‑5p is closely related to the development of several types of human cancers. However, the role of miR‑107‑5p in endometrial carcinoma (EC) has not been fully confirmed. In the present study, we aimed to explore the function of miR‑107‑5p in EC carcinogenesis. EC samples and normal endometrial tissues were obtained by laser capture microdissection. It was determined that the expression of miR‑107‑5p in EC was significantly higher than that in normal endometrium, and higher miR‑107‑5p expression was related to advanced FIGO stages, lymph node metastasis and myometrial invasion in EC patients. Blocking miR‑107‑5p significantly inhibited cell proliferation, migration and invasion of EC cells in vitro and in vivo. The results of bioinformatic algorithms and luciferase reporter assays revealed that estrogen receptor α (ERα) was a direct target of miR‑107‑5p. miR‑107‑5p downregulated the expression of ERα mRNA and protein. In conclusion, our results highlighted that miR‑107‑5p is a novel prognostic factor that targets ERα to promote tumor proliferation and invasion of EC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
3	Salvesen HB, Haldorsen IS and Trovik J: Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
4	Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al: Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol. 31:2607–2618. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chuffa LG, Lupi-Júnior LA, Costa AB, Amorim JP and Seiva FR: The role of sex hormones and steroid receptors on female reproductive cancers. Steroids. 118:93–108. 2017. View Article : Google Scholar : PubMed/NCBI
6	Rosenfeld MG and Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 276:36865–36868. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
9	Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N and Aoki D: MicroRNAs in endometrial cancer. Int J Clin Oncol. 18:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
10	Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 12:1552013. View Article : Google Scholar : PubMed/NCBI
11	Chen L, Li ZY, Xu SY, Zhang XJ, Zhang Y, Luo K and Li WP: Upregulation of miR-107 inhibits glioma angiogenesis and VEGF expression. Cell Mol Neurobiol. 36:113–120. 2016. View Article : Google Scholar : PubMed/NCBI
12	Lu C, Xie Z and Peng Q: MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873. 2017.PubMed/NCBI
13	Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Bao W, Qiu H, Yang T, Luo X, Zhang H and Wan X: Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 8:e706162013. View Article : Google Scholar : PubMed/NCBI
16	Chen J, Zhou X, Xiao Q, Wang T, Shao G, Li Y and Zhang Z: MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β. Hum Cell. 31:42–49. 2018. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Chen F, Zhao M, Yang Z, Zhang S, Ye L, Gao H and Zhang X: MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3′UTR. Biochem Biophys Res Commun. 480:455–460. 2016. View Article : Google Scholar : PubMed/NCBI
18	Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, et al: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 3:e40292008. View Article : Google Scholar : PubMed/NCBI
19	Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J and Matias-Guiu X: Endometrial carcinoma: Molecular alterations involved in tumor development and progression. Oncogene. 32:403–413. 2013. View Article : Google Scholar : PubMed/NCBI
20	Schouten LJ, Goldbohm RA and van den Brandt PA: Anthropometry, physical activity, and endometrial cancer risk: Results from the Netherlands cohort study. Int J Gynecol Cancer. 16 Suppl 2:S4922006. View Article : Google Scholar
21	Dedes KJ, Wetterskog D, Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen WY: Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab. 22:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
23	Chuffa LG, Seiva FR, Fávaro WJ, Amorim JP, Teixeira GR, Mendes LO, Fioruci-Fontanelli BA, Pinheiro PF, Martinez M and Martinez FE: Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate sex steroid receptors in the ovaries, oviducts, and uteri of adult rats. Reprod Toxicol. 39:40–49. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G and Simon R: Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol. 216:151–157. 2008. View Article : Google Scholar : PubMed/NCBI
25	Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H and Hollema H: Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 112:537–542. 2009. View Article : Google Scholar : PubMed/NCBI
26	Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Ishikawa N, et al: ESR1 gene amplification in endometrial carcinomas: A clinicopathological analysis. Anticancer Res. 33:3775–3781. 2013.PubMed/NCBI
27	Ohshiro K, Mudvari P, Meng QC, Rayala SK, Sahin AA, Fuqua SA and Kumar R: Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol. 24:914–922. 2010. View Article : Google Scholar : PubMed/NCBI
28	Giacinti L, Claudio PP, Lopez M and Giordano A: Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 11:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
29	Pelekanou V, Kampa M, Gallo D, Notas G, Troullinaki M, Duvillier H, Jacquot Y, Stathopoulos EN, Castanas E and Leclercq G: The estrogen receptor alpha-derived peptide ERα17p (P₂₉₅-T₃₁₁) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERα status. Mol Oncol. 5:36–47. 2011. View Article : Google Scholar : PubMed/NCBI
30	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
31	Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
32	Wu W, Lin Z, Zhuang Z and Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009. View Article : Google Scholar : PubMed/NCBI
33	Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, et al: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 124:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI
34	Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
35	Chen L, Zhang R, Li P, Liu Y, Qin K, Fa ZQ, Liu YJ, Ke YQ and Jiang XD: P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci Lett. 534:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
36	Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
37	Li X, Zhang Y, Shi Y, Dong G, Liang J, Han Y, Wang X, Zhao Q, Ding J, Wu K, et al: MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med. 15:1887–1895. 2011. View Article : Google Scholar : PubMed/NCBI
38	Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, et al: A MicroRNA targeting dicer for metastasis control. Cell. 141:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
39	Zhou C, Li G, Zhou J, Han N, Liu Z and Yin J: miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. PLoS One. 9:e1118602014. View Article : Google Scholar : PubMed/NCBI